16 results about "Colon carcinoma" patented technology

The invention discloses a preparation method and application of a tridentate metal iridium complex, the preparation method of the tridentate metal iridium complex comprises the following steps: step 1, substituted 1, 3-benzene diformate and 2-aminothiophenol are subjected to cyclization reaction to obtain a first intermediate; 2, reacting iridium trichloride hydrate with the first intermediate obtained in the step 1 to obtain a second intermediate; and step 3, reacting an LX ligand with the second intermediate obtained in the step 2, and then using silver trifluoromethanesulfonate to obtain a target product. The tridentate clamp type metal iridium complex disclosed by the invention is composed of a substituted-1, 3-bis (benzothiazolyl) benzene main ligand, a 2, 2-dipyridyl or phenanthroline NN ligand and balanced chloride ions. The complex is simple in synthesis method and has high cytotoxicity to cervical cancer cells, colon cancer cells and lung cancer cells, and the in-vitro cell toxicity of the complex is obviously superior to that of clinically applied anti-tumor drug cis-platinum, so that the complex has a good application prospect in the field of metal anti-cancer drugs.

The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

The application discloses a benzamide derivative, a preparation method and application thereof, and belongs to the field of organic synthesis. The benzamide derivative is prepared by adding a reactant of formula-2 into a reaction bottle, then adding a solvent A, and then adding an intermediate of formula-3, and then performing a reaction in the presence of a base; after the reaction is completed, water is added for dilution, and the benzamide derivative is obtained by extracting with ethyl acetate, concentrating the ethyl acetate layer under reduced pressure, and purifying the crude product. The benzamide derivative has a significant effect in an in-vitro anti-tumor activity test, and especially shows excellent anti-proliferation capacity on human colon cancer cells HCT116. The synthesis route is simple, the atomic economy is high, the cost is low, and the method is beneficial to large-scale implementation.

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

The application relates to the technical field of nanomaterials, in particular to an EpCAM aptamer modified nanomaterial and a preparation method and application thereof, wherein the nanomaterial takes carboxylated mesoporous silica nanoparticles as a carrier, and an EpCAM specific DNA aptamer is covalently coupled to the surface of the nanomaterial; the sequence of the EpCAM specific DNA aptamer is shown as SEQ ID No. 1. The nanomaterial can specifically capture tumor-derived exosomes (EVs) in blood, and can realize sensitive detection of EVs in the 7-day (early stage) and 21-day (late stage) stages of an HT29 colon cancer model and the 7-day stage of an A549 / H460 lung cancer model, thereby providing a minimally invasive liquid biopsy new tool for early diagnosis of colon cancer and lung cancer, and solving the inherent limitation problems of sensitivity and specificity of existing diagnosis means in cancer detection.

The application discloses a kind of multi-organ segmentation systems and colon cancer detection systems based on deep learning, multi-organ segmentation system includes: image processing module, for converting CT image into NIFTI three-dimensional image format, carries out data standardization processing;Again divide several sub three-dimensional images;Multi-organ detection segmentation module is used to the spleen, right kidney, left kidney, liver, aorta, inferior vena cava region in CT image is segmented.The colon cancer detection system includes: image processing module;Detection segmentation module is used to the colon cancer region in PET-CT image is segmented;Quantitative analysis module is used to the standard uptake value of colon cancer region is quantitatively analyzed.The application realizes the segmentation of each region in CT image;While the colon cancer lesion in PET-CT image is segmented, the standard uptake value of lesion region is quantitatively analyzed;Give consideration to the simplicity of operation, the accuracy of segmentation result and quantitative analysis function, realize the accurate segmentation and automatic analysis function of colon cancer region.

The application discloses a butenolide compound from a marine fungus, a preparation method and application thereof, and has the advantages that the butenolide compound is a novel compound discovered from metabolic products of Aspergillus terreus, similar skeleton compounds have not been reported, and the application proves for the first time that the butenolide compound has better tumor cell proliferation inhibition ability on colon cancer cells compared with other butenolide compounds.

In alternative embodiments, provided are immunohistochemical (IHC) methods and kits for reproducibly determining and scoring the degree of expression of protein tyrosine protein kinase-like 7 (PTK7), also known as colon cancer kinase 4 (CCK4), in a tissue sample; hER2 or a receptor tyrosine protein kinase erbB-2, or a cluster of differentiation 340 (CD340); a programmed death ligand 1 (PD-L1) or a differentiation cluster 274 (CD274); a B7 homolog 1 (B7-H1); and Ki-67 or MKI67 (a proliferation marker Ki-67), as well as a use thereof. In alternative embodiments, methods and kits are provided for diagnosing or selecting an individual eligible for treatment with a cancer or tumor therapeutic agent, or assessing the risk of cancer or tumor recurrence using an IHC method as provided herein. In alternative embodiments, kits comprising components and instructions for performing the methods as provided herein are provided. Described herein are methods for scoring PTK7 expression and utilizing the score as a companion or supplemental diagnosis to help treat or ameliorate cancer or tumor.

Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduced. The compound of the present invention is suitable for treating all tumors having high expression of CD44, comprising but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like.

The invention relates to a dammarendiol derivative as well as a preparation method and application thereof, and belongs to the technical field of biochemistry. The structure of the dammarendiol derivative is shown as a formula (1). # imgabs0 #, formula (1); in formula (1), R is # imgabs 1 # or # imgabs 2 #. Pharmacological experiments prove that the dammarendiol derivative has an obvious anti-tumor effect, has a better inhibition effect on human breast cancer cells, colon cancer cells, ovarian cancer cells and gastric cancer cell lines than positive control drugs, and can be used as a lead compound or a candidate compound for development of anti-tumor drugs.

The present invention provides an inhibitor capable of inhibiting the expression of PCDHA11 and inhibiting the function of PCDHA11. Specifically, the present invention provides nucleic acid molecules such as siRNA or antisense nucleic acids that inhibit PCDHA11 expression. These inhibitors are effective against gastric cancer, pancreatic cancer, breast cancer, esophageal squamous cell carcinoma, lung adenocarcinoma, colon cancer, and the like, and can be used as pan-cancer therapeutics.

The present invention provides a method of treating melanoma and other cancers in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an herbal extract of PHY906 or Scutellaria baicalensis, a fraction thereof or any active chemical present in the herbal extract or fraction thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract, a fraction thereof or any active chemical present in the herbal extract or fraction thereof, of at least one herb selected from the group consisting of Glycyrrhiza uralensis, Paeonia lactiflora, and Ziziphus jujuba. The methods of the invention are useful for treating cancer such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer and pancreatic cancer. In certain embodiments, administration of the herbal extracts of the invention counteract one or more gastrointestinal side effects of the immune checkpoint inhibitors and / or increase their therapeutic index against cancer.

The present invention relates to use of a PI3Kα-mutant selective inhibitor, specifically, use of compound 1, a racemate, a stereoisomer, or a pharmaceutically acceptable salt thereof, in the preparation of a drug for preventing and / or treating HR-positive / HER2-negative breast cancer, colon cancer, and head and neck cancer. The compound 1 can inhibit the growth of HR-positive / HER2-negative breast cancer cells, colon cancer cells, and head and neck squamous cell carcinoma cells, and can be used in combination with a CDK4 / 6 inhibitor or a selective ER degrading agent, having better therapeutic efficacy and good safety.

A humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.

The invention relates to the technical field of biomedicine, in particular to a marker for identifying and diagnosing colon cancer stem cells and an identification method of the marker, the marker is CLDN2 protein, the CLDN2 protein is composed of an amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence which has at least 90% sequence identity with the SEQ ID NO: 1 and keeps the activity of the colon cancer stem cell marker, and the marker is CLDN2 protein. It is found and confirmed that CLDN2 can be used as a specific marker for differential diagnosis of colon cancer stem cells for the first time, especially can effectively distinguish colon cancer stem cells from normal intestinal stem cells, and solves the technical problem that an existing marker is difficult to distinguish tumor stem cells from normal stem cells. The invention discloses a molecular mechanism that CLDN2 promotes beta-cat nin nuclear translocation by regulating ubiquitination modification of a K63 site of LASP1 so as to regulate and control functions of the colon cancer stem cells.